The purpose of this study is to evaluate the safety and tolerability of JNJ-440 in healthy and Chronic Hepatitis B (CHB) participants after single and multiple doses; and to evaluate the pharmacokinetic (PK) of JNJ-440 in healthy participants and in CHB participants following single and multiple dose regimens, administered alone (healthy participants and CHB participants).
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Parts 1, 2, and 3: Number of Participants With Adverse Events (AEs) as a Measure of Safety and Tolerability
Timeframe: Approximately up to 8 weeks
Parts 1, 2, and 3: Number of Participants With Clinically Significant Changes in Physical Examination (Body Weight Measurement and Skin Examination)
Timeframe: Approximately up to 8 weeks
Parts 1, 2, and 3: Number of Participants With Clinically Significant Changes in Vital Signs
Timeframe: Approximately up to 8 weeks
Parts 1, 2, and 3: Number of Participants With ECG Abnormalities
Timeframe: Approximately up to 8 weeks
Parts 1, 2, and 3: Number of Participants With Holter Monitoring Abnormalities
Timeframe: Up to 24 hours post-dose on Day 1
Parts 1, 2, and 3: Number of Participants With Clinical Laboratory Abnormalities
Timeframe: Approximately up to 8 weeks
Part 1: Maximum Observed Plasma Concentration (Cmax)
Timeframe: Day 1 (predose and at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72, 96, and 120 hours postdose)
Part 1: Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Time (AUC [0-last])
Timeframe: Day 1 (predose and at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72, 96, and 120 hours postdose)
Part 1: Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC[0-infinity])
Timeframe: Day 1 (predose and at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72, 96, and 120 hours postdose)
Part 3: Maximum Observed Plasma Concentration (Cmax)
Timeframe: Day 1 (predose, and at 0.5, 1, 2, 4, 8, and 12 hours post dose), morning predose on Days 2, 15 and 21, and Day 28 (predose, and at 0.5, 1, 2, 4, 8, and 12 hours postdose; 24 hours postdose [once daily {QD} dosing only])
Part 3: Observed Plasma Concentration From Time 0 to tau Hours Postdose (C[0-tau])
Timeframe: Day 1 (predose, and at 0.5, 1, 2, 4, 8, and 12 hours post dose), morning predose on Days 2, 15 and 21, and Day 28 (predose, and at 0.5, 1, 2, 4, 8, and 12 hours postdose; 24 hours postdose [QD dosing only])
Part 3: Area Under the Curve From Time Zero to End of Dosing Interval (AUC[0-tau])
Timeframe: Day 1 (predose, and at 0.5, 1, 2, 4, 8, and 12 hours post dose), morning predose on Days 2, 15 and 21, and Day 28 (predose, and at 0.5, 1, 2, 4, 8, and 12 hours postdose; 24 hours postdose [QD dosing only])